Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coltsfoot root is the dried rhizome of the perennial herbaceous plant *Tussilago farfara*, a member of the Asteraceae family. Historically, it has been employed in traditional herbal medicine as an antitussive and expectorant to treat respiratory conditions such as chronic cough, bronchitis, and asthma. Its therapeutic profile is primarily attributed to its high mucilage content, which provides a demulcent effect by soothing irritated mucous membranes, and flavonoids that may offer mild anti-inflammatory activity. However, the root naturally contains unsaturated pyrrolizidine alkaloids (PAs), including senkirkine and senecionine, which are known to be hepatotoxic and carcinogenic. Consequently, the medicinal use of coltsfoot root is strictly regulated or discouraged in many jurisdictions unless certified PA-free varieties are used. It is typically available as a botanical extract or as part of herbal tea formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on coltsfoot root.